In 2016, the newly established World Health Organization (WHO) classification of CNS tumors added molecular genetic features including isocitrate dehydrogenase (IDH) and chromosomal 1p/19q status to the previous version, which solely histologically classified gliomas into four grades (2). Despite very comprehensive treatment protocols consisting of debulking surgery, chemotherapy, and concomitant radiotherapy (3), the median survival of grade IV glioblastoma multiforme (GBM) is only 12–14 months (4). This evidence concerns the gene IDH1 and glioblastoma.